CORONA Remedies Limited has informed the Exchange about copy of newspaper publication of Audited Financial Results for the fourth quarter and year ended on March 31, 2026

CORONA Remedies Limited has published its audited financial results for the fourth quarter and year ended March 31, 2026. On a standalone basis, total income from operations grew to Rs. 5,786.52 million in Q4 FY26 compared to Rs. 1,503.81 million in Q4 FY25, showing strong sequential and year-on-year improvement. For the full year ended March 2026, total income stood at Rs. 44,537.68 million. Profit after tax for Q4 FY26 was Rs. 293.69 million versus Rs. 714.53 million in Q4 FY25, while full year PAT reached Rs. 1,182.31 million. On a consolidated basis, total income for Q4 FY26 was Rs. 6,095.99 million with consolidated PAT of Rs. 608.51 million, and full year consolidated PAT was Rs. 3,456.06 million. Basic EPS for Q4 standalone was Rs. 15.64 per share. The results were reviewed by the Audit Committee and approved by the Board on May 11, 2026, and audited by Deloitte Haskins & Sells LLP.